MBX
HEALTHCAREMBX Biosciences Inc
$32.12+2.52 (+8.51%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MBX Today?
No stock-specific AI insight has been generated for MBX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$9.43$44.89
$32.12
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS$-2.38
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume466K
Avg Volume (10D)—
Shares Outstanding47.6M
MBX News
21 articles- MBX Biosciences (MBX) CEO logs small 607-share tax sell-to-cover tradeStock Titan·May 9, 2026
- MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate HighlightsYahoo Finance·May 7, 2026
- MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant AwardYahoo Finance·May 7, 2026
- 3 Overlooked Stocks Set to Soar in 2026Motley Fool·May 5, 2026
- MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity PortfolioYahoo Finance·Apr 23, 2026
- Aaron Wealth Makes a Big Bet on MBX Biosciences With a 1.1 Million Share PurchaseMotley Fool·Apr 22, 2026
- Microbix Engages with Diagnostics Industry ExpertsYahoo Finance·Apr 20, 2026
- Microbix Presenting at the 2026 Bloom Burton ConferenceYahoo Finance·Apr 16, 2026
- Microbix Exhibiting & Presenting at ESCMID Global 2026Yahoo Finance·Apr 15, 2026
- Does MBX (MBX) Options-Driven Breakout Reveal Deeper Shifts In Its Investment Narrative?Yahoo Finance·Apr 4, 2026
- MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 3, 2026
- MBX CEO Buys 18,500 Shares as Stock Jumps 270% This Past Year. Here's What You Should KnowMotley Fool·Mar 26, 2026
- Microbix Announces Annual Meeting Voting ResultsYahoo Finance·Mar 26, 2026
- Microbix Presents Reference-Material Innovations at EUROGINYahoo Finance·Mar 17, 2026
- MBX Phase 3 Plans And New CBO Sharpen Rare Disease FocusYahoo Finance·Mar 16, 2026
- MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate HighlightsYahoo Finance·Mar 12, 2026
- MBX Biosciences Appoints Karen Basbaum as Chief Business OfficerYahoo Finance·Mar 10, 2026
- CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for HypoparathyroidismYahoo Finance·Mar 9, 2026
- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for HypoparathyroidismYahoo Finance·Mar 9, 2026
- MBX Biosciences CFO Shift Puts Funding And Execution In FocusYahoo Finance·Mar 7, 2026
- MBX Biosciences Calls 2026 “Pivotal” With Phase 3 Plans, Obesity Program, and $460M Cash RunwayMarketbeat·Mar 1, 2026
All 21 articles loaded
Price Data
Open$30.05
Previous Close$29.60
Day High$32.33
Day Low$29.06
52 Week High$44.89
52 Week Low$9.43
52-Week Range
$9.43$44.89
$32.12
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS$-2.38
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume466K
Avg Volume (10D)—
Shares Outstanding47.6M
About MBX Biosciences Inc
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. The company is headquartered in Carmel, Indiana.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—